Partnership agreement: Astra Zeneca and Pierre Fabre Médicament
January 17, 2013
On 19 December Pierre Fabre Médicament signed a partnership agreement with AstraZeneca for a period of three years whereby it will provide exclusive promotion of Zoladex® in France.
Zoladex® is a treatment for metastatic prostate cancer. Prostate cancer is now the leading cancer in men aged over 50 and the presence of bone and visceral metastases in 15 to 20% of cases is a poor prognostic factor.
Zoladex® will be promoted by the Ligne Générale [General Line] networks in private surgeries and by Oncology in hospitals.
This new agreement is part of a new move to recognise PFM as the partner of choice in onco-urology, with Zoladex® now complementing the range which already comprises Permixon®, a long-standing product of our group indicated in the treatment of benign prostate hypertrophy, Ormandyl® and Javlor®.
Zoladex® promotion will begin during the first quarter of 2013.